MYMingkun Yu

Mingkun Yu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mingkun Yu has a total of 43 co-authors. Here are the top co-authors by number of shared publications:

  • Catherine Jan

    Department of Ophthalmology and Surgery, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Victoria, Australia

    1 shared publication
  • Chang-Hao Liang

    Centre for Evidence-based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China

    1 shared publication
  • Changhao Liang

    Centre for Evidence-based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China

    1 shared publication
  • Chengze Li

    College of Integrated Traditional Chinese and Western Medicine, Binzhou Medical University, Yantai, Shandong Province, China

    1 shared publication
  • Deng Pan

    School of Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China

    1 shared publication
  • Fanlong Bu

    Centre for Evidence-based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China

    1 shared publication

Latest Publications

  • Integrated analysis and functional validation reveal KCNQ1 tumor suppressor targeting by dahuang Zhechong Pills via cuproptosis modulation in colorectal cancer

    by Pengfei Wang, Pengpeng Dong, Zikai Geng, Yizhuo Gong, Wenze Cui, Wenhuan Song, Yiyang Liu, Wenhao Yu, Lianzhi Ren, Jiantao Lv, et al.

  • Open Access

    Pseudomyopia as an independent risk factor for myopia onset: a prospective cohort study among school-aged children

    by Wei Sun, Mingkun Yu, Jianfeng Wu, Xiaotong Han, Catherine Jan, Jike Song, Wenjun Jiang, Zihang Xu, Ziyun Wu, Jing Xu, et al.

    Aim To investigate whether pseudomyopia is an independent risk factor for myopia onset based on a population-based cohort study. Methods Non-myopic children were recruited from schools in rural and urban settings of Shangdong province, China. Baseline examinations started in September 2020 and all participants were invited for a 6-month follow-up. Pseudomyopia was defined as spherical equivalent (SE) ≤−0.50 diopters (D) before cycloplegia and >−0.50D after cycloplegia. Myopia was defined as cycloplegic SE ≤−0.50D. Results A total of 2328 children (baseline age: 4–17 years) were included in the final analysis. During the 6-month follow-up, 21.1% (355/1680) pseudomyopic eyes developed myopia, and 3.8% (110/2879) non-myopic and non-pseudomyopic eyes developed myopia. After adjusting for multiple myopia risk factors, including baseline cycloplegic SE, near work and outdoor time, pseudomyopia was found to be an independent risk factor for myopia onset (relative risk=2.52, 95% CI 1.86 to 3.42). Additionally, pseudomyopic children with more myopic cycloplegic SE (pConclusion This is an important longitudinal study to prove that pseudomyopia is an independent risk factor for myopia development among school-aged children.


  • The Process factors and improvement strategies of patient compliance and retention in clinical trials: a synthesis of qualitative research

    by Mingkun Yu, Changhao Liang, Qian He, Kexin Liu, Yuting Feng, Qianyun Chai, Jianping Liu, Yutong Fei

    INPLASY202120024 The Process factors and improvement strategies of patient compliance and retention in clinical trials: a synthesis of qualitative research Keywords: qualitative research; factors; strategies; compliance; retention. Download PDF – 202120024

  • Open Access

    Berberine for diarrhea in children and adults: a systematic review and meta-analysis

    by Mingkun Yu, Xuejing Jin, Changhao Liang, Fanlong Bu, Deng Pan, Qian He, Yang Ming, Paul Little, Hongbo Du, Shibing Liang, et al.

    Background: Diarrhea is a ubiquitous digestive system disease, leading to loss of fluid and electrolytes, and may be life-threatening, especially in children and adults who are immunosuppressed or malnourished. Berberine has a broad-spectrum antibiotic activity and is very widely used to treat diarrhea in China. No systematic review has been carried out to evaluate the evidence presented in clinical trials. The aim of this study was to assess the effectiveness and safety of berberine in diarrhea treatment among children and adults. Methods: Seven databases and two clinical trial registries were searched on 1 September 2019. Randomized controlled trials were included, where participants were diagnosed (first diagnosed) as having diarrhea according to clear diagnostic criteria. Berberine alone or in combination with Western medication as intervention were included. Subgroup analyses were conducted based on children or adults, acute or persistent diarrhea, infectious or noninfectious and treatment courses. Primary outcomes were clinical cure rate and duration of diarrhea. The GRADE tool was used to assess the quality of evidence. Results: A total of 38 randomized controlled trials were included involving 3948 participants (including 27 trials on 2702 children) were included. Compared with antibiotics, berberine plus antibiotics showed better results in both adults and in children in general, especially when given for 7 days or 3 days in acute infectious diarrhea of children. Compared with the control groups, using berberine alone or in combination with montmorillonite, probiotics, and vitamin B increased the clinical cure rate of diarrhea. The use of berberine alone or berberine combined with montmorillonite reduced the duration of hospitalization. Using berberine had significantly better laboratory indicators (isoenzyme, inflammatory factors, myocardial enzyme, and fecal trait) and fewer systemic symptoms than the no berberine groups. Overall, 22 of 27 trials on children used berberine as an enema. No deaths and serious adverse events were reported. The quality of evidence of included trials was moderate to low or very low. The impact of different dosages, frequencies and treatment durations on the outcomes was not evaluated due to insufficient number of trials. Conclusion: This review demonstrated that berberine was generally effective in improving clinical cure rates and shortening the duration of diarrhea compared with control groups. No severe adverse event was reported. However, there is still a lack of high-quality evidence for evaluating the efficacy and safety of berberine. Trial registration: PROSPERO CRD42020151001 (available from http://www.crd.york.ac.uk/PROSPERO/ ).